ARCHIVES

Fragmin Cuts Risk Of VE By 50 Percent In Study

This article is from The Cancer Letter archive.

Vol. 26 No. 1 | January 31, 2003

Download PDF Visit The Full Archive

Related Articles

Soybean Studies, Computing Support Recompetition Ok’d

November 9, 1990

Blue Cross, Broder Skirmish On Coverage Of Group C Drugs

November 3, 1989

In Brief: Columbia’s Marks Reportedly Will Move To MSK; FDA Committee to Consider THC For Group C List

May 23, 1980

Cancer Panel: Lack Of Genetic Basis For Race Presents Dilemma For Studies; Data Collection Must Include Socioeconomic Measures, Report To Clinton Says

March 20, 1998

UK’s NICE Set to Deny Payments For Zaltrap In Second-Line Metastatic Colorectal Cancer

June 26, 2013

May issue of Business & Regulatory Report, 8 additional pages, included.

May 28, 2004